Tracked deals
14
14 tracked deals across 2020-2026.
Biotechnology Buyers & Acquisitions in New Jersey
Buyer mix
Mixed buyer set
9 strategic · 8 pe
Top trend
Volume peaked in 2024
3 tracked deals announced in 2024.
Primary Insight
What Stands Out
- Strategic portfolio expansion appears across oncology, onco-derm, and ophthalmology (e.g., Sun Pharma, CorMedix, Astellas).
- Enabling platform and technology moves show up alongside drug developers—collagen biopolymers (HTL), recombinant protein technology (Modern Meadow division), and liver co-culture models (BICO/Visikol).
- Public-company pathways and capital structures recur, including SPAC mergers and financing tied to completing a previously announced merger (Apimeds / MindWave).
- Recurring buyer names on New Jersey biotech transactions include Keen Vision Acquisition Corporation, TenX Keane Acquisition, HTL Biotechnology, CorMedix Inc., and Arsenal Capital Partners.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Access Biotechnology | 1 | Founding investor and PIPE lead supporting the transactio... | PE |
| Apimeds Pharmaceuticals US, Inc. | 1 | Clinical-stage biopharmaceutical company developing non-o... | Strategic |
| Arsenal Capital Partners | 1 | Private equity firm specializing in middle-market investm... | PE |
| Astellas Pharma Inc. | 1 | Global pharmaceutical company focused on discovering, dev... | Strategic |
| BICO | 1 | Public life-sciences / bio-convergence company offering l... | Strategic |
| Bain Capital Life Sciences | 1 | Participates in the PIPE as an investor. | PE |
| CorMedix Inc. | 1 | Biopharmaceutical company focused on developing and comme... | Strategic |
| Deep Track Capital | 1 | Participates in the PIPE as an investor. | PE |
| Farallon Capital Management | 1 | Participates in the PIPE as an investor. | PE |
| Full‑Life Technologies | 1 | Fully integrated radiopharmaceutical company operating R&... | Strategic |
Acquisition Volume in Biotechnology in New Jersey by Year
Last 7 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
June 29, 2026
- Buyer
- JATT II Acquisition Corp, Access Biotechnology, Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, JATT Ventures II L.P.
- Target
- Talawar Therapeutics, Talawar Tx Inc
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Talawar Therapeutics entered into a definitive business combination agreement with JATT II Acquisition Corp to create a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases. The transaction is expected to close in the second half of 2026 and includes an oversubscribed $225 million PIPE alongside $60 million held in JATT II’s trust account (assuming no redemptions).
-
March 24, 2026
- Buyer
- Apimeds Pharmaceuticals US, Inc.
- Target
- MindWave Innovations Inc.
- Seller
- Inscobee Inc., Apimeds Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Apimeds Pharmaceuticals US, Inc. announced a settlement with Inscobee Inc. and Apimeds Inc. that resolves disputes tied to the previously announced merger with MindWave Innovations Inc. The settlement clears the way to complete the merger transactions and effect the company’s $100 million PIPE financing to support ongoing biotech initiatives, including Lōkahi Therapeutics’ Apitox program.
-
August 7, 2025
- Buyer
- CorMedix Inc.
- Target
- Melinta Therapeutics, LLC
- Seller
- Affiliates of Deerfield Management Company, L.P.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
CorMedix Inc. has entered into a definitive agreement to acquire Melinta Therapeutics, paying $300 million upfront (including $260 million cash and $40 million in CorMedix equity to Melinta shareholders), plus up to $25 million in a regulatory milestone and tiered royalties. The deal is expected to close in September, subject to customary closing conditions and U.S. regulatory approval.
-
May 30, 2025
- Buyer
- Sun Pharmaceutical Industries Limited
- Target
- Checkpoint Therapeutics, Inc.
- Seller
- Fortress Biotech, Inc., Armistice Capital Master Fund Ltd. (managed by Armistice Capital LLC)
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Sun Pharmaceutical Industries Limited has completed the acquisition of Checkpoint Therapeutics, Inc., acquiring all outstanding shares for $4.10 per share in cash plus a contingent value right. The deal gives Sun Pharma ownership of UNLOXCYT (cosibelimab-ipdl), the FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma, and expands its oncology/onco-derm product portfolio.
-
- Buyer
- Keen Vision Acquisition Corporation
- Target
- Medera Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Keen Vision Acquisition Corporation (KVAC) entered into a definitive merger agreement with clinical-stage biotechnology company Medera Inc. to take Medera public on Nasdaq, expected to close in the fourth quarter of 2024. The business combination is expected to provide funds that will accelerate Medera’s three most advanced AAV-based gene therapy programs.
-
August 12, 2024
- Buyer
- TenX Keane Acquisition
- Target
- Citius Oncology, Inc., Citius Pharmaceuticals’ wholly owned oncology subsidiary
- Seller
- Citius Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
TenX Keane Acquisition is merging with Citius Pharmaceuticals’ wholly owned oncology subsidiary to create a new publicly traded company, Citius Oncology, Inc. (expected Nasdaq ticker CTOR), with Citius Pharma retaining majority control (about 90%). The transaction is positioned to support commercialization of LYMPHIR and exploration of additional targeted oncology assets.
-
- Buyer
- HTL Biotechnology
- Target
- Modern Meadow (beauty & biomedical division)
- Seller
- Modern Meadow
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Divestiture
HTL Biotechnology has acquired the beauty and biomedical division of American company Modern Meadow, including its recombinant proteins platform and leading human recombinant collagen type III (rhCOL3) technology. The deal expands HTL's biopolymer portfolio and R&D/manufacturing capabilities, strengthens its presence in North America, and accelerates development of cosmetic and medical-grade recombinant collagen products.
-
April 29, 2023
- Buyer
- Astellas Pharma Inc.
- Target
- IVERIC bio, Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Astellas Pharma has agreed to acquire 100% of IVERIC bio for $40.00 per share, implying an aggregate equity value of roughly $5.9 billion. The acquisition strengthens Astellas' ophthalmology capabilities and adds Iveric's lead program avacincaptad pegol (ACP) for geographic atrophy secondary to AMD to Astellas' pipeline.
-
April 27, 2023
- Buyer
- Healthwell Acquisition Corp. I, HWEL Holdings Corp. (Pubco)
- Target
- Starton Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Starton Therapeutics and Healthwell Acquisition Corp. I entered into a definitive business combination agreement under which a newly formed Pubco subsidiary of Healthwell will acquire Starton and become a publicly traded company. The transaction is expected to close in the second half of 2023 and is designed to commercialize Starton’s proprietary continuous delivery technology for oncology therapeutics, including programs in multiple myeloma and chronic lymphocytic leukemia.
-
December 8, 2022
- Buyer
- Arsenal Capital Partners
- Target
- Certara, Inc.
- Seller
- Funds controlled by EQT Private Equity
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Growth capital
Arsenal Capital Partners closed a previously announced $449 million stock purchase in Certara, acquiring shares from funds controlled by EQT Private Equity and becoming a long-term minority investor. As part of the transaction Arsenal appointed Operating Partner David Spaight to Certara's board while Stephen McLean remains a director; Arsenal agreed to a two-year lock-up on the newly purchased shares.
-
November 28, 2022
- Buyer
- Full‑Life Technologies
- Target
- Focus‑X Therapeutics
- Seller
- Focus‑X Therapeutics shareholders, Viva Biotech (portfolio investor)
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Full‑Life Technologies, a global radiotherapeutics company, agreed to acquire New Jersey‑based Focus‑X Therapeutics to expand its peptide‑focused radiopharmaceutical pipeline. Focus‑X shareholders are eligible for an upfront payment plus up to $245 million in development, regulatory and sales milestones and royalties; the deal was expected to close in Q1 2023.
-
- Buyer
- SFW Capital Partners
- Target
- Sannova Analytical, Inc.
- Seller
- Marepalli family, Dr. Venkat Reddy, Malleswar Kollu, Geeta Vidiyala, Founders and existing owners
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Growth capital
SFW Capital Partners completed a strategic growth investment in Sannova Analytical, a Somerset, New Jersey-based bioanalytical CRO that provides bioanalytical and CMC testing services to pharmaceutical and biotech companies. Founders and existing owners (including the Marepalli family, Dr. Venkat Reddy, Malleswar Kollu, and Geeta Vidiyala) are reinvesting and retaining an equity stake; SFW will support expansion of services, capacity, and pursue strategic acquisitions to accelerate growth.
-
September 15, 2021
- Buyer
- BICO, Visikol
- Target
- HUREL Corp.
- Seller
- HUREL Corp.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
BICO has acquired the assets and operations of HUREL Corp., a US-based provider of 2D liver co-culture models and assay services, for approximately USD 2.5 million. The HUREL portfolio and team will be integrated into BICO subsidiary Visikol to expand the group's liver in vitro model and assay offerings for pharma, biotech and academic customers.
-
September 13, 2020
- Buyer
- Gilead Sciences, Inc.
- Target
- Immunomedics
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Frequently Asked Questions
Which kinds of biotech transactions are shown for New Jersey?
The page includes a mix of strategic acquisitions (for products and programs), technology/platform acquisitions (for enabling capabilities), and SPAC-style mergers that lead to public companies.
Do these deals focus mainly on drug products or broader biotech capabilities?
Both. Several transactions expand therapeutic portfolios (including oncology/onco-derm and ophthalmology), while others add enabling technologies and services such as recombinant proteins and in vitro models/assays.
Are New Jersey deals limited to one type of buyer?
No. Buyers range from pharmaceutical companies (e.g., Sun Pharmaceutical Industries Limited, Astellas Pharma Inc., CorMedix Inc.) to technology and platform-focused biotech acquirers (e.g., HTL Biotechnology, BICO) and SPAC-linked entities (e.g., Keen Vision Acquisition Corporation, TenX Keane Acquisition).
What geography do the transactions cover?
The listed activity is tied to New Jersey, United States in the deal summaries provided.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2026
Biotechnology Acquisitions in 2025
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2022
Biotechnology Acquisitions in 2021
Acquisitions in New Jersey
Private Equity-Backed Acquisitions in New Jersey
Acquisitions in New Jersey in 2026